Q2 FY2026 EarningsQ2 FY26 results beat consensus across the top and bottom lines: revenue was $8.2M vs. $7.5M expected, and GAAP gross margin reached 53% vs. 49% expected. Consumable sales grew 31% YoY, signaling strong clinical adoption of Optical Genome Mapping (OGM). Management issued Q3 revenue guidance of $8.2M–$8.6M and maintained FY26 guidance of $31M–$33M, generally aligning with or slightly exceeding market expectations.
Financial report interval: 2026.03.30 - 2026.06.30
Overview: Bionano Genomics(BNGO) the Revenue is 8.171 M (+21.36%), Beat estimate;the EBIT is -7.218 M (+6.71%), Beat estimate;the EPS is -0.64 (+67.84%), Beat estimate.
Actual
YoY
Estimate
YoY
Vs estimate
YoY
RevenueExceed expectations
0.01B21.36%
0.01B11.04%
+0.00B10.32%
EBITExceed expectations
-0.01B6.71%
-0.01B2.90%
+0.00B3.81%
EPSExceed expectations
-0.6467.84%
-0.6766.33%
+0.03001.51%
Revenue
ActualEstimateUnit: USD
qf
EBIT
ActualEstimateUnit: USD
qf
Net income
ActualEstimateUnit: USD
qf
EPS
ActualEstimateUnit: USD
qf